Evidence map›Paper›PMID 26258995›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2015

Inhibitory Effects of PEI-RGD/125I-(αv) ASODN on Growth and Invasion of HepG2 Cells.

Haidong Cai, Yu Qiao, Ming Sun, Xueyu Yuan, Qiong Luo, Yuehua Yang, Shidong Yuan, Zhongwei Lv

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Frontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haidong CaiDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Yu QiaoDepartment of Blood Transfusion, Changhai Hospital, Second Military Medical University, Shanghai, China (mainland).
Ming SunDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Xueyu YuanDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Qiong LuoDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Yuehua YangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Shidong YuanDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).
Zhongwei LvDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China (mainland).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the in vitro inhibitory effects of PEI-RGD/125I-(αv)ASODN (PEI, polyethylenimine; RGD, Arg-Gly-Asp; ASODN, antisense oligodeoxynucleotide) on the growth and invasion of HepG2 cells. MATERIAL AND

methodsASODN of the integrin αv-subunit was marked with 125I and underwent complexation with PEI-RGD, a PEI derivative. Next, PEI-RGD/125I-(αv) ASODN was introduced into HepG2 cells via receptor-mediated transfection, and its inhibition rate on HepG2 cell growth was tested using the methyl thiazolyl tetrazolium (MTT) method. The effects of PEI-RGD/125I-(αv) ASODN on HepG2 cell invasion ability were evaluated using the Boyden chamber assay.

results1) The 125I marking rate of (αv) ASODN was 73.78±4.09%, and the radiochemical purity was 96.68±1.38% (greater than 90% even after a 48-h incubation period at 37°C), indicating high stability. 2) The cytotoxicity assays showed that the cell inhibition rates did not differ significantly between the PEI-RGD/125I-(αv)ASODN group and the PEI-RGD/(αv) ASODN group, but they were both significantly higher than in the other groups and were positively correlated (r=0.879) with the dosage within a certain range. 3) The invasion assays showed that the inhibition rate was significantly greater in the PEI-RGD/125I-(αv) ASODN group compared to the other groups.

conclusionsPEI-RGD/125I-(αv) ASODN can efficiently inhibit the growth and proliferation of HepG2 cells and can also weaken their invasive ability.

Indexed as

Base SequenceCell ProliferationHep G2 CellsHumansIntegrin alphaVIodine RadioisotopesNeoplasm InvasivenessOligodeoxyribonucleotides, AntisenseOligopeptidesPolyethyleneiminearginyl-glycyl-aspartic acidIntegrin alphaVIodine RadioisotopesOligodeoxyribonucleotides, AntisenseOligopeptidesPolyethyleneimine

Identifiers

PMID26258995
PMCPMC4536871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.